Novo Nordisk's Buyback Tally, Awiqli Approval and CagriSema Data Take a Back Seat to 4 November
Published on 10/28/2026 at 12:10 | Editorial boerse-global.de
Novo Nordisk has repurchased 40,274,179 B shares as of Friday, a mandatory disclosure that puts a hard number on the Danish drugmaker's capital-return programme. The transactions carry a value of DKK 11,187,348,102 against a ceiling of up to DKK 15 billion for the entire scheme.
The distinction matters. Monday's announcement documents purchases already executed inside an existing framework rather than any fresh expansion of it, and the programme's upper limit is a cap, not a sum already spent. What the filing does establish is that capital is being returned; it says nothing about revenue growth, margins or demand for individual medicines.
A pediatric label, and a drug still in the pipeline
For a read on the commercial side, investors have to look elsewhere. On Friday the FDA cleared Awiqli as an adjunct to diet and exercise to improve blood sugar control in children aged ten and older with type 2 diabetes. Novo Nordisk called it the first once-weekly insulin for this patient group, widening the product's US label.
That is a regulatory decision in hand. CagriSema is not. Roughly a week ago the company reported a post-hoc analysis of REDEFINE 1 in which women on the investigational candidate averaged 25.0% weight loss after 68 weeks — a figure drawn from the efficacy evaluation under assumed optimal treatment conditions. The placebo arm averaged 3.0%, and the subgroup findings were presented at the annual meeting of the Menopause Society.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Read the whole trial rather than the subgroup, and the picture shifts: Reuters reported an average weight loss of 22.7% across the full study, short of the 25% Novo Nordisk had targeted.
A courtroom rebuff that settles nothing
The advertising dispute with Eli Lilly remains a separate drag. US District Judge Zahid Quraishi declined to grant the preliminary ad injunction Novo Nordisk sought, according to Reuters, finding the evidence of harm insufficient; Lilly's commercials may keep running while the underlying false-advertising suit proceeds. The ruling does not end the litigation — it means the requested pause was not obtained.
Set against that, the medical progress reads as a counterweight rather than a resolution. An expanded approval opens additional treatment options without answering what financial contribution it will make, and data from a candidate still under development cannot be weighed the same way as a label already granted.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
The date that frames everything
All of it now yields to 4 November, when Novo Nordisk is scheduled to publish results for the first nine months of 2026, with a conference call to follow. That report is the next concrete occasion to judge the business, and it demands a clean separation between operating performance and medical milestones — particularly for developments that arrived after the reporting period, which may shape what comes next but cannot retroactively explain the nine-month figures. Until then, the buyback notice stands as evidence of the capital programme in motion, without getting ahead of the trading story.
Ad
Novo Nordisk Stock: New Analysis - 28 October
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
